Home > Cardiology > Studies show cardiovascular benefit with sotagliflozin

Studies show cardiovascular benefit with sotagliflozin

New England Journal of Medicine
AHA 2020
Reuters Health - 17/11/2020 - For patients with type 2 diabetes and chronic kidney disease, treatment with the diabetes drug sotagliflozin produced a 26% reduction in key cardiovascular events, including heart failure, according to results from the SCORED study released Monday. Meanwhile, the drug significantly cut the risk of cardiovascular death and lowered the burden of treatment for heart failure by 33%, according to findings from the SOLOIST-WHF trial, also released Monday at the American Heart Association Scientific Sessions meeting. Both studies were published online by The New England Journal of Medicine. Sotagliflozin is part of a class of drugs known as sodium-glucose cotransporter 2 (SGLT2) inhibitors. On top of prior studies of SGLT2 inhibitors, the two new ones "show the data are overwhelming that the majority of patients with diabetes who have heart failure or chronic kidney disease, barring a complication, should be an SGLT2 inhibitor" r...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on